Search | Clinical Trials Finder

Conditions: Fibromyalgia
Interventions: CBT and milnacipran, CBT with a placebo, Educational with milnacipran; Other · Behavioral · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Malaria
Interventions: Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions: SPR720, Placebo, Open-label Standard of Care; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more

Conditions: OSA, Obstructive Sleep Apnea
Interventions: Acetazolamide, Eszopiclone, Placebo, Venlafaxine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Type 1 Diabetes Mellitus
Interventions: teplizumab, Placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 34
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 30 more

Conditions: Alzheimer's Disease
Interventions: Group 1 ELND005, Group 2 ELND005; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more

Conditions: Depression
Interventions: TMS, D-serine, Placebo; Device · Drug · Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Pharmacokinetics
Interventions: TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Eosinophilic Esophagitis
Interventions: EUR-1100, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Pain
Interventions: Fentanyl, oxycodone/acetaminophen; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Montgomery, Alabama • Sun City West, Arizona • Palm Desert, California + 14 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Redlands, California • Sherman Oaks, California • Wildomar, California + 24 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 53
States / cities: Concord, California • La Jolla, California • Los Angeles, California + 47 more

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: AIN457 150mg, AIN457 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Fresno, California • Pasadena, California • Sacramento, California + 28 more

Conditions: Postmenopausal Osteoporosis
Interventions: AGA2118, Placebo; Drug · Other
Lead sponsor: Angitia Biopharmaceuticals; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more

Conditions: Uncontrolled Asthma
Interventions: Tralokinumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 103
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 79 more

Conditions: Healthy Adults
Interventions: EC5026 oral capsule, Placebo oral capsule; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more

Conditions: Psoriasis
Interventions: 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more

Conditions: Asthma
Interventions: minocycline, Placebos; Drug
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Acute Uncomplicated Diverticulitis
Interventions: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, Placebo, Metronidazole, Cefuroxime; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Migraine
Interventions: Nasal CO2, Inactive Placebo; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Stanford, California • East Hartford, Connecticut + 12 more

Search by objective public record fields.

Drug and Talk Therapy for Fibromyalgia

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Pharmacologic Augmentation of TMS for Depression With D-serine

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

A Study in Prevention of Re-emergence of Depression Symptoms

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines